Form 8-K Axsome Therapeutics, For: Aug 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq reach record closing highs as focus pivots to earnings
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Caribou Biosciences to halt CAR-T programs, explore sale
- Stryker names Spencer Stiles as CEO, Lobo moves to chair
- Francis Halzen wins Nobel physics prize for Antarctic 'ghost particle' hunt
Cowen Reiterates Outperform, $130 PT on Axsome Therapeutics (AXSM) Following FDA Approval
August 19, 2022 10:39 AM EDTCowen analyst Joseph Thome reiterated an Outperform rating and $130.00 price target on Axsome Therapeutics (NASDAQ: AXSM) following news that AXS-05 (Auvelity) has been approved for the treatment of MDD nearly one year after the therapy's initial PDUFA date.
The analyst... More



